FDA’s OPDP untitled letters show rising scrutiny of DTC ads’ overall impression on consumers and urge companies to balance ...

On this week's episode of the Business of Biotech, William Ho, CEO of IN8bio, explains why gamma delta T cells may have an edge against cancer, including solid tumors like glioblastoma. He also offers ...

The global pharmaceutical supply chain has been under intense scrutiny since the COVID-19 pandemic exposed its heavy reliance on concentrated Active Pharmaceutical Ingredient (API) manufacturing hubs.

Individualized genetic medicine is moving faster than the traditional drug approval model was built to handle. Genome editing, RNA-based medicines, and other targeted therapies can now be designed for ...

Achieving regulatory approval for a new drug is an extraordinary achievement. The bar for success is high. Many companies with breakthrough scientific discoveries and promising clinical data still ...

I spent years prosecuting traffickers of street drugs like meth and fentanyl, but the drug crisis that should most concern life sciences companies is a less visible illicit drug market: one that ...

Most emerging life sciences companies already understand the importance of thinking about the future patient. Leadership teams routinely model future treatment pathways, reimbursement environments, ...

In ophthalmic trials, operational execution has a direct impact on endpoint quality. Precision assessments often depend on specialized equipment, trained personnel, and strict adherence to visit ...

On this week's episode of the Business of Biotech, Tyler Menichiello, chief editor at Bioprocess Online, host of the Better Biopharma podcast, and my Life Science Connect (LSC) colleague, convenes the ...

In this segment from the Life Science Leader Live event “Overcoming Operational Challenges And New Opportunities,” Dr. Ebrahim Delpassand, founder, chairman and CEO at RadioMedix, explains why ...

In this segment from the Life Science Leader Live event “Overcoming Operational Challenges And New Opportunities,” panelists talk about the importance of harmonization across regulatory agencies ...

In this segment from the Life Science Leader Live event “Overcoming Operational Challenges And New Opportunities,” Richard Valeix, CEO at Telix Therapeutics describes the on-demand requirements for ...